Imeik Technology Development Co

Imeik Technology Development Co OCF/Debt

The Operating Cash Flow to Debt Ratio of Imeik Technology Development Co (300896.SZ) as of Oct 23, 2026 is 4,286.46 %. In the previous year, Operating Cash Flow to Debt Ratio was 3,724.65 % — a change of 15.08% (higher).

OCF/Debt

4,286.46 %

YoY

15.08%

Last updated:

Operating Cash Flow to Debt Ratio of Imeik Technology Development Co is 2024 4,286.46 % . Operating Cash Flow to Debt Ratio of Imeik Technology Development Co was 2023 3,724.65 % . It decreases by 15.08% higher compared to the previous year.

The Imeik Technology Development Co OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2017
1,530.16 CNY
Jan 1, 2021
1,959.16 CNY
Jan 1, 2022
2,000.26 CNY
Jan 1, 2023
3,724.65 CNY
Jan 1, 2024
4,286.46 CNY
The Imeik Technology Development Co OCF/Debt history
YEAROCF/DebtYoY
4,286.46 %+15.08%
3,724.65 %+86.21%
2,000.26 %+2.10%
1,959.16 %+28.04%
1,530.16 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Imeik Technology Development Co Stock analysis

What does Imeik Technology Development Co do? Imeik Technology Development Co., Ltd. generates revenue through the research, development, and industrialization of biomedical materials, particularly recombinant proteins and peptides. The company focuses on products like injection-type sodium hyaluronate series and polydioxanone facial implants, which are used for facial and neck skin repair in medical cosmetology, surgical repair, and metabolic disease treatment. Its self-developed products target the Chinese market, where it has established a technology transformation platform for materials such as medical chitosan and polylactic acid. The firm leverages its industrialized product lines to serve medical and cosmetic applications. The company's primary customers are healthcare providers and medical facilities in China that utilize its products for skin repair, surgical procedures, and metabolic disease management. Its product portfolio includes sodium hyaluronate series for injections, polydioxanone facial implants, and other biomedical materials like medical chitosan and polylactic acid. These products are sold under the company's own brand, with no external brands mentioned in the description. Imeik's business model centers on the industrialization of its self-developed biomedical materials, transforming research into commercial products for medical and cosmetic use. The firm's focus on recombinant proteins and peptides drives its product development, targeting applications in medical cosmetology and surgical repair. It operates within the Chinese market, where it has established a technology platform for product transformation and commercialization. Imeik Technology Development Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Imeik Technology Development Co stock

Operating Cash Flow to Debt Ratio of Imeik Technology Development Co is 4,286.46 % in 2024.

Operating Cash Flow to Debt Ratio of Imeik Technology Development Co changed from 3,724.65 % to 4,286.46 %, representing a 15.08% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio Imeik Technology Development Co since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's Imeik Technology Development Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Imeik Technology Development Co

All Key Metrics — Imeik Technology Development Co